Characteristic neuropathologic changes in Alzheimer disease (AD) are amyloid-β deposits and neurofibrillary tangles. Recently, a new radioligand for amyloid senile plaques, (11)C-labeled 5-(6-{[tert-butyl(dimethyl)silyl]oxy}-1,3-benzothiazol-2-yl)pyridin-2-amine ((11)C-AZD2184), was developed, and it was reported to show rapid brain uptake followed by rapid washout. In this study, (11)C-AZD2184 binding in control subjects and AD patients was examined in more detail by compartment model analysis using a metabolite-corrected arterial input function. The accuracy of simplified quantitative methods using a reference brain region was also evaluated
Alzheimer’s disease (AD) is characterized by a progressive accumulation of amyloid plaques, neurofib...
Diagnosis and treatment strategies for dementia are based on the sensitive and specific detection of...
Current Positron Emission Tomography (PET) biomarkers for Alzheimer’s disease (AD) assess either neu...
Characteristic neuropathologic changes in Alzheimer disease (AD) are amyloid-β deposits and neurofib...
Objectives: Characteristic neuropathologic changes in Alzheimer disease (AD) are amyloid-beta depos...
Background and aims:[11C]AZD2184 has been recently developed as an amyloid imaging PET ligand that h...
The characteristic neuropathological changes in Alzheimer\u27s disease (AD) are deposition of amyloi...
Objectives: The characteristic neuropathologic changes in Alzheimer disease (AD) are deposition of a...
Positron emission tomography (PET) allows for in vivo visualisation and quantification of amyloid-β ...
International audienceThe two main pathological hallmarks of Alzheimer’s disease (AD) in the brain a...
Background/Purpose: We have successfully visualized amyloid- (A) deposition in a mouse model of Alzh...
ObjectiveAlzheimer's disease (AD) is a neurodegenerative disease characterized by Aβ plaques in the ...
PurposeExtensive deposition of senile plaques and neurofibrillary tangles in the brain is a patholog...
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer’s disease (AD)...
Abstract Background Imaging agents capable of quantifying the brain’s tau aggregates will allow a mo...
Alzheimer’s disease (AD) is characterized by a progressive accumulation of amyloid plaques, neurofib...
Diagnosis and treatment strategies for dementia are based on the sensitive and specific detection of...
Current Positron Emission Tomography (PET) biomarkers for Alzheimer’s disease (AD) assess either neu...
Characteristic neuropathologic changes in Alzheimer disease (AD) are amyloid-β deposits and neurofib...
Objectives: Characteristic neuropathologic changes in Alzheimer disease (AD) are amyloid-beta depos...
Background and aims:[11C]AZD2184 has been recently developed as an amyloid imaging PET ligand that h...
The characteristic neuropathological changes in Alzheimer\u27s disease (AD) are deposition of amyloi...
Objectives: The characteristic neuropathologic changes in Alzheimer disease (AD) are deposition of a...
Positron emission tomography (PET) allows for in vivo visualisation and quantification of amyloid-β ...
International audienceThe two main pathological hallmarks of Alzheimer’s disease (AD) in the brain a...
Background/Purpose: We have successfully visualized amyloid- (A) deposition in a mouse model of Alzh...
ObjectiveAlzheimer's disease (AD) is a neurodegenerative disease characterized by Aβ plaques in the ...
PurposeExtensive deposition of senile plaques and neurofibrillary tangles in the brain is a patholog...
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer’s disease (AD)...
Abstract Background Imaging agents capable of quantifying the brain’s tau aggregates will allow a mo...
Alzheimer’s disease (AD) is characterized by a progressive accumulation of amyloid plaques, neurofib...
Diagnosis and treatment strategies for dementia are based on the sensitive and specific detection of...
Current Positron Emission Tomography (PET) biomarkers for Alzheimer’s disease (AD) assess either neu...